Navigation Links
MAP Pharmaceuticals to Present at the 2008 Citi Investment Research Global Healthcare Conference
Date:5/16/2008

MOUNTAIN VIEW, Calif., May 16 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will present at the 2008 Citi Investment Research Global Healthcare Conference on Wednesday, May 21, 2008, at 9:00 am (ET) in New York City.

A live webcast of the presentation will be available on the Investor Relations section of MAP Pharmaceuticals' website at http://www.mappharma.com. A replay will also be available within 24 hours for seven days following the presentation.

About MAP Pharmaceuticals, Inc.

MAP Pharmaceuticals develops and plans to commercialize new therapies for children and adults who suffer from chronic conditions that it believes are not adequately treated by currently available medicines. The Company applies its proprietary inhalation technologies to enhance the therapeutic benefits and commercial attractiveness of proven drugs while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. MAP Pharmaceuticals has two drug candidates, Unit Dose Budesonide and MAP0004, in late stage development for the potential treatment of pediatric asthma and migraine respectively. MAP Pharmaceuticals' pipeline also includes a drug candidate in early clinical development for the treatment of asthma and chronic obstructive pulmonary disease.

Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.


'/>"/>
SOURCE MAP Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences
2. Transdel Pharmaceuticals Closes $4 Million Financing
3. XTL Biopharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
4. Sagent Pharmaceuticals Provides US$20,000 in Aid to Earthquake-Devastated Areas in Central China
5. Access Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
6. Memory Pharmaceuticals Reports First Quarter 2008 Financial Results
7. Jazz Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
8. Peregrine Pharmaceuticals Reports Studies Published in Science Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
9. Medimetriks Pharmaceuticals, Inc. Begins Operations
10. SGX Pharmaceuticals Announces First Quarter Financial Results and Gives Pipeline Update
11. ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... , Belgium , Nov. 24, 2014 ... sciences company focused on developing diagnostic tests for cancer and ... cancer study will be presented at the Science for Business ... Belgium . The data come from VolitionRx,s ... at the Pneumology department of the Centre Hospitalier Universitaire (CHU) ...
(Date:11/24/2014)... (PRWEB) November 24, 2014 2014 ... Dihydrazide Industry is a professional and in-depth research ... Adipic Dihydrazide information, like its definition, classification, application, ... overview. This report covers the international market analysis, ... (such as the US, Europe, Asia, China, Japan ...
(Date:11/22/2014)... (PRWEB) November 21, 2014 Two new educational ... what comes next for ALS research and how the pharmaceutical ... After the Ice Bucket Challenge: Where Does the ALS Money ... Tuesday, 2 December 2014, Time: 1:30pm ET, Register ... expert speaker Dr. Merit Cudkowicz, Julianne Dorn Professor of Neurology ...
(Date:11/22/2014)... On November 17th Chicago start-up Briteseed ... Medical Technologies Summit in San Francisco to take first ... among Silicon Valley investors and technology elites as the ... also positions Briteseed to move on to the ... and compete with other elite innovation finalists for a ...
Breaking Biology Technology:VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 3VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 4VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 5VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 6Adipic Dihydrazide Industry 2019 Research Forecasts on Worldwide, China Regions Now Available at ReportsnReports.com 2Adipic Dihydrazide Industry 2019 Research Forecasts on Worldwide, China Regions Now Available at ReportsnReports.com 3DrugDev Webinars in December to Explore What Comes Next for ALS Research and How We Can Make Life Easier for Clinical Sites 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 3
... Presentation Scheduled for Monday, March 17th at 11:30am ET, ... KERX ) today announced that I. Craig Henderson, ... Vice President,Medical Affairs, are scheduled to present at the ... The presentation, which will take place on Monday, ...
... Phase 2 Clinical Trial in ... ... today financial results for the year ended December,31, 2007, and highlighted the ... ), During 2007, the Company achieved the following corporate milestones:, ...
... for ... cars, phones, computers, ARGONNE, Ill., ... Laboratory and Toda Kogyo Corp. (Toda) of Japan have,reached a ... patented composite cathode materials for lithium-ion,batteries, which result in longer-lasting, ...
Cached Biology Technology:Keryx Biopharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference 2Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results 2Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results 3Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results 4Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results 5Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results 6Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results 7Argonne's Lithium-Ion Battery Technology to be Commercialized by Japan's Toda Kogyo 2Argonne's Lithium-Ion Battery Technology to be Commercialized by Japan's Toda Kogyo 3
(Date:11/5/2014)... Fidel Santamaria, associate professor of biology in the ... researchers in the nation selected to receive a ... Grant for Exploratory Research (EAGER). The funding supports ... support researchers to create new technology that will ... Santamaria, complex behaviors in neuroscience are broken into ...
(Date:11/4/2014)... right amount of death at the right time might ... new research that could help in understanding animal populations, ... In a paper in the journal Trends in ... European colleagues conclude that the kind of positive population ... individuals, or mortality, depends on the size and developmental ...
(Date:11/4/2014)... , November 4, 2014   ... market growth   Fuel3D , a developer ... a funding round totaling $6.4 million (£4 million). This funding ... secured earlier this year and paves the way for the ... The funding round was led by Chimera Partners ...
Breaking Biology News(10 mins):UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3When less is more: Death in moderation boosts population density in nature 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3
... PHOENIX, Ariz. Feb. 5, 2010 The Translational ... a strategic alliance and affiliation agreement with the Van ... capabilities of both non-profit institutes. TGen expects ... aimed at developing new tests and treatments for patient ...
... study of children in Ukraine has found that for ... care and the relationship between children and their caregivers ... their findings, the researchers highlight the importance of comprehensive ... changing caregivers, working schedules and providing training to enhance ...
... Mich. In an effort to eliminate the tropical ... researcher has been awarded $2 million to reformulate an ... their tracks. Charles Mackenzie, a professor of veterinary ... the funding via a larger $13 million grant the ...
Cached Biology News:TGen finalizes alliance with Van Andel Research Institute 2TGen finalizes alliance with Van Andel Research Institute 3For HIV-infected children, quality of caregiver relationship is crucial 2MSU researcher awarded $2 million to tackle parasitic tropical diseases 2
MAb to Yersinia pestis F1 Ag. Yersinia pestis F1 Antigen EB Strain...
... FluoroGuard antifade reagent is ... confocal and standard fluorescence microscopy. ... photobleaching in a wide variety ... labeled with fluorescein, rhodamine, sulforhodamine ...
... UN-SCAN-IT gel Software converts any scanner ... has numerous options and features, the basic ... (TIFF, JPEG, PCX, BMP, etc.) into pixel ... simple steps. Turn your ...
... RED Chromogen System consists of FAST RED ... in the presence of alkaline phosphatase to ... The FAST RED System provides enough ... Contains: , , Vial A: 6 Tablets ...
Biology Products: